Genentech, Inc. - Product Pipeline Review - 2015

1 of 3
Genentech, Inc. - Product Pipeline Review - 2015

Summary

This, ‘Genentech, Inc. - Product Pipeline Review - 2015’, provides an overview of the Genentech, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Genentech, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Genentech, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Genentech, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Genentech, Inc.’s pipeline products

Reasons to buy

- Evaluate Genentech, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Genentech, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Genentech, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Genentech, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Genentech, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Genentech, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 3
List of Tables
List of Figures
Genentech, Inc. Snapshot
Genentech, Inc. Overview
Key Information
Key Facts
Genentech, Inc. - Research and Development Overview
Key Therapeutic Areas
Genentech, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Genentech, Inc. - Pipeline Products Glance
Genentech, Inc. - Late Stage Pipeline Products
Genentech, Inc. - Clinical Stage Pipeline Products
Genentech, Inc. - Early Stage Pipeline Products
Genentech, Inc. - Drug Profiles
etrolizumab
lampalizumab
taselisib
crenezumab
duligotuzumab
ipatasertib
lifastuzumab vedotin
pictilisib
polatuzumab vedotin
quilizumab
RG-6046
RG-7652
RG-7745
DLYE-5953A
DMUC-4064A
RG-6047
RG-7450
RG-7741
RG-7841
RG-7842
RG-7882
RG-7888
RG-7893
BV-6
CS-3
G007-LK
G244-LM
GNE-293
GNE-317
GNE-3511
GNE-7915
GNE-892
MAb-30D8
Monoclonal Antibody Conjugate for Cancer
Monoclonal Antibody to Inhibit Tau for Alzheimer's Disease
MV-1
Small Molecule to Inhibit BACE1 for Alzheimer’s Disease
Small Molecule to Inhibit MAP4K4 for Cancer
Small Molecule to Inhibit PI3K for Cancer
Small Molecule to Inhibit TYK2 for Psoriasis and IBD
Small Molecules to Inhibit JAK2 for Cancer
Small Molecules to Inhibit JAK2 for Myeloproliferative Neoplasms
Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma
Small Molecules to Inhibit Mammalian Rapamycin Kinase for Prostate Cancer
Small Molecules to Inhibit NAMPT for Cancer
Small Molecules to Inhibit PI3-Kinase Delta for Inflammatory and Leukocyte Disorders
Monoclonal Antibody Conjugated for Cancer
Small Molecule 2 for Undisclosed Indication
Small Molecule to Inhibit ITK for Allergic Asthma
Small Molecules 1 for Undisclosed Indication
Small Molecules for Bacterial Infections
Small Molecules for Central Nervous System Disorders
Small Molecules for Undisclosed Indication
Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation
Small Molecules to Inhibit Jak1/2 for Hematopoietic and Immunologic diseases
Small molecules to Inhibit Pim Kinase for Multiple Myeloma
Genentech, Inc. - Pipeline Analysis
Genentech, Inc. - Pipeline Products by Target
Genentech, Inc. - Pipeline Products by Route of Administration
Genentech, Inc. - Pipeline Products by Molecule Type
Genentech, Inc. - Pipeline Products by Mechanism of Action
Genentech, Inc. - Recent Pipeline Updates
Genentech, Inc. - Dormant Projects
Genentech, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Genentech, Inc. - Company Statement
Genentech, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Genentech, Inc. - Key Manufacturing Facilities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Genentech, Inc., Key Information
Genentech, Inc., Key Facts
Genentech, Inc. - Pipeline by Indication, 2015
Genentech, Inc. - Pipeline by Stage of Development, 2015
Genentech, Inc. - Monotherapy Products in Pipeline, 2015
Genentech, Inc. - Partnered Products in Pipeline, 2015
Genentech, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
Genentech, Inc. - Out-Licensed Products in Pipeline, 2015
Genentech, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
Genentech, Inc. - Phase III, 2015
Genentech, Inc. - Phase II, 2015
Genentech, Inc. - Phase I, 2015
Genentech, Inc. - Preclinical, 2015
Genentech, Inc. - Discovery, 2015
Genentech, Inc. - Pipeline by Target, 2015
Genentech, Inc. - Pipeline by Route of Administration, 2015
Genentech, Inc. - Pipeline by Molecule Type, 2015
Genentech, Inc. - Pipeline Products by Mechanism of Action, 2015
Genentech, Inc. - Recent Pipeline Updates, 2015
Genentech, Inc. - Dormant Developmental Projects,2015
Genentech, Inc. - Discontinued Pipeline Products, 2015
Genentech, Inc., Other Locations
Genentech, Inc., Subsidiaries
Genentech, Inc., Key Manufacturing Facilities

List of Figures
Genentech, Inc. - Pipeline by Top 10 Indication, 2015
Genentech, Inc. - Pipeline by Stage of Development, 2015
Genentech, Inc. - Monotherapy Products in Pipeline, 2015
Genentech, Inc. - Partnered Products in Pipeline, 2015
Genentech, Inc. - Out-Licensed Products in Pipeline, 2015
Genentech, Inc. - Pipeline by Top 10 Target, 2015
Genentech, Inc. - Pipeline by Top 10 Route of Administration, 2015
Genentech, Inc. - Pipeline by Top 10 Molecule Type, 2015
Genentech, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll